vs
伯乐实验室（BIO）与布鲁克（BRKR）财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是伯乐实验室的1.4倍（$977.2M vs $693.2M）。伯乐实验室净利率更高（103.9% vs 2.7%，领先101.2%）。伯乐实验室同比增速更快（3.9% vs -0.2%）。布鲁克自由现金流更多（$207.2M vs $119.1M）。过去两年布鲁克的营收复合增速更高（16.4% vs 6.5%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
BIO vs BRKR — 直观对比
营收规模更大
BRKR
是对方的1.4倍
$693.2M
营收增速更快
BIO
高出4.1%
-0.2%
净利率更高
BIO
高出101.2%
2.7%
自由现金流更多
BRKR
多$88.1M
$119.1M
两年增速更快
BRKR
近两年复合增速
6.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $977.2M |
| 净利润 | $720.0M | $26.0M |
| 毛利率 | 49.8% | 46.0% |
| 营业利润率 | -17.2% | 7.8% |
| 净利率 | 103.9% | 2.7% |
| 营收同比 | 3.9% | -0.2% |
| 净利润同比 | 200.6% | 89.8% |
| 每股收益（稀释后） | $26.59 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOBRKR
| Q4 25 | $693.2M | $977.2M | ||
| Q3 25 | $653.0M | $860.5M | ||
| Q2 25 | $651.6M | $797.4M | ||
| Q1 25 | $585.4M | $801.4M | ||
| Q4 24 | $667.5M | $979.6M | ||
| Q3 24 | $649.7M | $864.4M | ||
| Q2 24 | $638.5M | $800.7M | ||
| Q1 24 | $610.8M | $721.7M |
净利润BIOBRKR
| Q4 25 | $720.0M | $26.0M | ||
| Q3 25 | $-341.9M | $-59.6M | ||
| Q2 25 | $317.8M | $7.6M | ||
| Q1 25 | $64.0M | $17.4M | ||
| Q4 24 | $-715.8M | $13.7M | ||
| Q3 24 | $653.2M | $40.9M | ||
| Q2 24 | $-2.2B | $7.6M | ||
| Q1 24 | $383.9M | $50.9M |
毛利率BIOBRKR
| Q4 25 | 49.8% | 46.0% | ||
| Q3 25 | 52.6% | 44.1% | ||
| Q2 25 | 53.0% | 44.9% | ||
| Q1 25 | 52.3% | 48.8% | ||
| Q4 24 | 51.2% | 50.4% | ||
| Q3 24 | 54.8% | 48.4% | ||
| Q2 24 | 55.6% | 48.0% | ||
| Q1 24 | 53.4% | 48.9% |
营业利润率BIOBRKR
| Q4 25 | -17.2% | 7.8% | ||
| Q3 25 | 10.0% | -6.0% | ||
| Q2 25 | 11.8% | 1.5% | ||
| Q1 25 | 4.0% | 4.0% | ||
| Q4 24 | 8.7% | 7.4% | ||
| Q3 24 | 9.9% | 7.9% | ||
| Q2 24 | 15.9% | 6.0% | ||
| Q1 24 | 7.3% | 9.0% |
净利率BIOBRKR
| Q4 25 | 103.9% | 2.7% | ||
| Q3 25 | -52.4% | -6.9% | ||
| Q2 25 | 48.8% | 1.0% | ||
| Q1 25 | 10.9% | 2.2% | ||
| Q4 24 | -107.2% | 1.4% | ||
| Q3 24 | 100.5% | 4.7% | ||
| Q2 24 | -339.2% | 0.9% | ||
| Q1 24 | 62.9% | 7.1% |
每股收益（稀释后）BIOBRKR
| Q4 25 | $26.59 | $0.10 | ||
| Q3 25 | $-12.70 | $-0.41 | ||
| Q2 25 | $11.67 | $0.05 | ||
| Q1 25 | $2.29 | $0.11 | ||
| Q4 24 | $-25.89 | $0.09 | ||
| Q3 24 | $23.34 | $0.27 | ||
| Q2 24 | $-76.26 | $0.05 | ||
| Q1 24 | $13.45 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $298.8M |
| 总债务越低越好 | $1.2B | $1.9B |
| 股东权益账面价值 | $7.5B | $2.5B |
| 总资产 | $10.6B | $6.2B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.76× |
8季度趋势，按日历期对齐
现金及短期投资BIOBRKR
| Q4 25 | $1.5B | $298.8M | ||
| Q3 25 | $1.4B | $293.1M | ||
| Q2 25 | $1.4B | $92.0M | ||
| Q1 25 | $1.7B | $184.2M | ||
| Q4 24 | $1.7B | $183.4M | ||
| Q3 24 | $1.6B | $148.1M | ||
| Q2 24 | $1.6B | $169.7M | ||
| Q1 24 | $1.6B | $340.1M |
总债务BIOBRKR
| Q4 25 | $1.2B | $1.9B | ||
| Q3 25 | $1.2B | $2.0B | ||
| Q2 25 | — | $2.4B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $1.4B |
股东权益BIOBRKR
| Q4 25 | $7.5B | $2.5B | ||
| Q3 25 | $6.7B | $2.4B | ||
| Q2 25 | $7.1B | $1.8B | ||
| Q1 25 | $6.7B | $1.8B | ||
| Q4 24 | $6.6B | $1.8B | ||
| Q3 24 | $7.5B | $1.8B | ||
| Q2 24 | $6.8B | $1.8B | ||
| Q1 24 | $9.1B | $1.4B |
总资产BIOBRKR
| Q4 25 | $10.6B | $6.2B | ||
| Q3 25 | $9.7B | $6.4B | ||
| Q2 25 | $10.2B | $6.3B | ||
| Q1 25 | $9.5B | $5.9B | ||
| Q4 24 | $9.4B | $5.8B | ||
| Q3 24 | $10.6B | $6.1B | ||
| Q2 24 | $9.7B | $5.9B | ||
| Q1 24 | $12.6B | $4.5B |
负债/权益比BIOBRKR
| Q4 25 | 0.16× | 0.76× | ||
| Q3 25 | 0.18× | 0.83× | ||
| Q2 25 | — | 1.34× | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | 0.18× | 1.18× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 1.21× | ||
| Q1 24 | — | 0.97× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $229.8M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $207.2M |
| 自由现金流率自由现金流/营收 | 17.2% | 21.2% |
| 资本支出强度资本支出/营收 | 6.6% | 2.3% |
| 现金转化率经营现金流/净利润 | 0.23× | 8.84× |
| 过去12个月自由现金流最近4个季度 | $374.6M | $43.3M |
8季度趋势，按日历期对齐
经营现金流BIOBRKR
| Q4 25 | $164.9M | $229.8M | ||
| Q3 25 | $120.9M | $-33.2M | ||
| Q2 25 | $116.5M | $-127.5M | ||
| Q1 25 | $129.9M | $65.0M | ||
| Q4 24 | $124.2M | $190.0M | ||
| Q3 24 | $163.6M | $38.4M | ||
| Q2 24 | $97.6M | $1.1M | ||
| Q1 24 | $69.8M | $21.8M |
自由现金流BIOBRKR
| Q4 25 | $119.1M | $207.2M | ||
| Q3 25 | $89.2M | $-54.1M | ||
| Q2 25 | $70.8M | $-148.8M | ||
| Q1 25 | $95.5M | $39.0M | ||
| Q4 24 | $81.2M | $153.3M | ||
| Q3 24 | $123.4M | $5.8M | ||
| Q2 24 | $55.4M | $-23.5M | ||
| Q1 24 | $29.6M | $400.0K |
自由现金流率BIOBRKR
| Q4 25 | 17.2% | 21.2% | ||
| Q3 25 | 13.7% | -6.3% | ||
| Q2 25 | 10.9% | -18.7% | ||
| Q1 25 | 16.3% | 4.9% | ||
| Q4 24 | 12.2% | 15.6% | ||
| Q3 24 | 19.0% | 0.7% | ||
| Q2 24 | 8.7% | -2.9% | ||
| Q1 24 | 4.8% | 0.1% |
资本支出强度BIOBRKR
| Q4 25 | 6.6% | 2.3% | ||
| Q3 25 | 4.9% | 2.4% | ||
| Q2 25 | 7.0% | 2.7% | ||
| Q1 25 | 5.9% | 3.2% | ||
| Q4 24 | 6.4% | 3.7% | ||
| Q3 24 | 6.2% | 3.8% | ||
| Q2 24 | 6.6% | 3.1% | ||
| Q1 24 | 6.6% | 3.0% |
现金转化率BIOBRKR
| Q4 25 | 0.23× | 8.84× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.37× | -16.78× | ||
| Q1 25 | 2.03× | 3.74× | ||
| Q4 24 | — | 13.87× | ||
| Q3 24 | 0.25× | 0.94× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | 0.18× | 0.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
